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Background: Centralized spirometry may significantly improve quality of spirometry and reduce variability of this outcome measure in
clinical trials in cystic fibrosis (CF).
Methods: Spirometry was performed during the phase 2 randomized, placebo-controlled, double-blind clinical trial of denufosol in patients
with mild to moderate CF using American Thoracic Society guidelines. Uniform spirometers were used with electronic data transmission of
all the data to a reading center. Spirometry was evaluated for quality by a central reader based on start of test, cough during the test, and
evidence of a plateau.
Results: A total of 1418 spirometry values were assessed in 89 subjects during the trial. In only 5 instances did the central reading center need
to give feedback to sites regarding the quality of spirometry. The study site data matched the central reading center's data for all but 78 (6%)
spirometry values in 33 patients. Many of these differences were small with only 35 (3%) values differing by more than 50 mL in 26 patients.
Conclusion: Spirometry in this clinical trial was of high quality with low rate of significant centralized over-read.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Spirometry; Clinical trials; Outcome measures; Cystic fibrosis; Centralized1. Introduction
Cystic fibrosis (CF) is one of the most common inherited
fatal diseases in Caucasians with a reported incidence of CF
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doi:10.1016/j.jcf.2007.07.00630 years, the median age of survival has improved from
14 years in 1969 to over 35 years in 2004 in the United States
[2]. Advancing the care of patients with CF requires the
continued search for more efficacious treatments that can
modify the natural history of the disease and improve symptom
control and prognosis. Improving treatment options for
patients with CF requires outcome measures that are clinically
relevant and readily responsive to changewith treatments. One
of the most commonly used outcome measures in CF has been
lung function. Lung function is primarily assessed via
spirometry, principally using the measure of forced vital
capacity (FVC) and forced expiratory volume in the firsted by Elsevier B.V. All rights reserved.
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outcome measures in both randomized clinical trials and
epidemiologic studies related to lung disease in CF; FEV1
continues to be one of the most important surrogate endpoints
to document response to therapy. Improvement in lung
function has been used to gain approval from the Food and
Drug Administration (FDA) for two important therapies in the
treatment of CF [recombinant human deoxyribonuclease
(DNase), and inhaled tobramycin] [3,4].
As with any clinical endpoint used in clinical trials,
improving accuracy and precision of spirometry is integral to
decreasing both biased results and excessive variability of
results. Irwin and colleagues have clearly shown that
variability can bias the measurement of lung function due
to regression to the mean [5]. High quality spirometry relies
on the actual spirometer, the technician performing the study,
the patient's participation during the study, and lastly the
patient's true lung function. Centralized spirometry is one
approach to potentially reduce variability of spirometry.
Centralized spirometry incorporates standardized instrumen-
tation, site/technician training, centralized review by an
expert over-reader, and immediate feedback to sites on poor-
quality test sessions. This program is put in place to ensure
that spirometry is performed according to American
Thoracic Society (ATS) standards; merely stating that these
standards are employed in a clinical trial does not mean that
they are indeed rigorously applied [6].
Only limited data exist regarding the impact of centralized
spirometry on spirometry performed in clinical trials [7–12].
These studies suggest that centralized spirometry can reduce
variability in spirometry in clinical trials in studies involving
patients with both asthma and chronic obstructive lung disease.
Given these data,we prospectively assessed the impact of using
centralized spirometry in a phase 2 multi-center randomized
double-blind placebo-controlled trial in patients with CF.
2. Methods
2.1. Participants
Subjects in this study were all participants in a multi-
center, double-blind, randomized, placebo-controlled trial
(DBPCRCT) comparing the safety and efficacy of three dose
levels of inhaled denufosol, a novel P2Y2 receptor agonist,
to placebo in subjects with mild to moderate CF lung disease;
the goal of this novel agent is to improve lung function in
patients with CF. Results from this study are reported by
Deterding et al. [13]. This DBPCRCT trial was conducted
within the CF Therapeutics Development Network (CF TDN)
with six additional sites from outside the network. This clinical
trial network is funded by the National Institutes of Health and
Cystic Fibrosis Therapeutics, Inc. and currently has 18 major
CF clinical sites situated around the United States representing
the largest CF centers caring for both pediatric and adult CF
patients in the nation. A full description of this clinical trial
network has been previously reported [14].To be included in this clinical trial, patients had to have a
confirmed diagnosis of CF, be 8 years of age or greater and
less than or equal to 50 years of age, have an oxygen
saturation N 90% on room air, have a negative pregnancy test
at the screening visit (all females of childbearing potential),
be clinically stable with no evidence of acute upper or lower
respiratory tract infection or current pulmonary exacerbation,
have an FEV1 percent of predicted greater than 75%, and be
able to reproducibly perform spirometry maneuvers. Repro-
ducibility was defined as repeated FEV1 within 12% on two
separate occasions separated by 1–7 days. Key exclusion
criteria included abnormal renal or liver function; HRCT
scan at screening with clinically significant findings atypical
for moderate CF; changes in physiotherapy technique,
bronchodilator, anti-inflammatory, or corticosteroid medica-
tions during the week prior to screening; and use of certain
concomitant medications that could have affected study
measurements, including the use of TOBI® or other inhaled
antibiotics within 30 days prior to screening or anti-
pseudomonal antibiotics, oral macrolide antibiotics or
intravenous (IV) antibiotics within 14 days prior to
screening. The data for this analysis were anonymous and
are included in the Therapeutics Development Network Data
Bank, which is approved by the Institutional Review Board
at Children's Hospital and Regional Medical Center in
Seattle, WA.
2.2. Design and procedures
The Vitalograph® Spirotrac Centralized Spirometry
System was used for this study. The centralized spirometry
program was overseen by Pharmaceutical Research Associ-
ates (PRA), Inc., Lenexa, Kansas; PRA acted as the central
reading center for the study. The centralized spirometry
program included initial site education when the spirometers
were delivered to each site, an educational session at the
investigator meeting, and feedback regarding the site
performance of spirometry during the conduct of the study.
Each site was provided with the same spirometer: a
Vitalograph 6800 spirometer attached to a PC running the
software “Spirotrac for Over-Read.” The Spirotrac spirom-
eter provides two different reports for a session. The first
report shows results only from the three “best” tests (i.e., the
tests with the largest values of (FVC+FEV1)), along with a
“best” column that shows the largest value of FEV1 among
the best tests, the largest value of FVC among the best tests,
and the value of FEF25–75 associated with the largest value of
(FVC+FEV1) among the best tests. The second report
presents results for all tests that were performed, both
acceptable and unacceptable. Unacceptable tests are noted
with error flags that indicate the problem with the test.
Spirometry was conducted using ATS Standards [6] using a
standard operating procedure developed at the CF Thera-
peutics Development Network. The sites were instructed to
pick the best FEV1 (i.e., largest FEV1) and best FVC (i.e.,
largest FVC) from all acceptable curves as per the ATS
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and reported on the case report forms.
The actual spirometry data, including the spirograms
(volume–time and flow–volume), were then transmitted
electronically to a central reading center for over-reading.
The central over-reader assessed the loops for: quality based
on start of test; cough in the first second during the test; and
evidence of a plateau at the end of the maneuver. The over-
reader may or may not have agreed with: 1) what the
computer said was acceptable or unacceptable, and 2) what
the site research coordinator (RC) said was acceptable. The
over-reader included comments if there was disagreement
(e.g., over-reader does not agree with the site RC about a
particular test the RC said is acceptable).
To evaluate the potential impact of centralized spirometry
on variability in lung function assessed during a clinical trial,
we compared spirometry data from the denufosol study
gathered during the first two clinic visits, which occurred
prior to initiation of active drug or placebo, with pooled
pre-dose data from two previous studies [15,16] conducted
within the CF TDN which used similar sites and inclusion
criteria and which did not use centralized spirometry.
Spirometry values used in the comparison included only
those values from screening and baseline visits prior to
initiation of any drug therapy. To ensure that subjects had
similar lung function, only those subjects with an FEV1%
predicted N 75% were included in the analysis, matching the
lung function entry criteria for the denufosol study. The
percent predicted values for FEV1 and FVC were calculated
using the reference equations of Knudson et al. [17].
2.3. Statistical analysis
The results of both the central over-read values and site
values were compared. Several results are possible from this
comparison: 1) the site chooses the “correct” value, enters it
correctly; 2) the site chooses the “correct” value but enters itTable 1
Demographic and baseline characteristics by treatment group for the ITT populati
Characteristic Placebo (N=21) Denufosol
20 mg (N=23)
Age, years, mean, (SD) 15.8 (7.78) 14.3 (7.43)
Male, n (%) 15 (71) 16 (70)
Caucasian, n (%) 21 (100) 23 (100)
CF genotype, n (%)
ΔF508 homozygous 9 (43) 13 (57)
ΔF508 heterozygous 9 (43) 6 (26)
Other 3 (14) 4 (17)
Height, cm, mean (SD) 156.00 (16.313) 148.29 (18.968)
Weight, kg, mean (SD) 50.83 (14.620) 44.61 (18.811)
FEV1 (L) 2.690 (0.7967) 2.389 (0.9094)
FEV1 % predicted, mean (SD) 92.678 (10.6774) 93.936 (9.4483)
FEF % predicted, mean (SD) 78.924 (27.8006) 84.719 (23.3562)
P. aeruginosa positive a, n (%) 6 (29) 11 (48)
a A patient is considered positive for Pa if the patient's culture at screening was
history of two known positive bronchoalveolar lavage or sputum cultures within tincorrectly; and 3) the site chooses an “incorrect” value.
Spirometry was measured at all clinic visits. Two clinic visits
occurred prior to dosing (Visits 1 and 2), followed by four
post-treatment visits (Visits 3–6). Because denufosol is an
investigational drug, in this analysis we were not interested
in modeling efficacy for the post-treatment visits (efficacy
results are presented in Deiterding et al. [13]). Instead, we
were interested in looking at agreement between spirometry
measures reported at a site and reported by the over-reader.
We were also interested in comparing variability within
subjects prior to dosing in this study versus variability within
subjects prior to dosing in previous studies.
Site and central reading center parameter values (FEV1
and FVC) were compared by computing differences in the
values at each visit. Linear mixed-effects models were used to
account for repeated measures within subjects and estimate
variance components [18].Mean absolute difference between
center and site values within subject was compared between
sites using the Kruskal–Wallis test [19]. Within-subject
variability was assessed using spirometry values obtained at
screening and baseline (pre-1st dose) spirometry. Absolute
difference in lung function from screening to baseline was
compared between studies using the two-sample t-test, and
compared within the denufosol study for values with and
without over-read using the paired t-test. We used SAS 8.2
for Windows (SAS Institute Inc., Cary, NC) and S-PLUS 6.2
and 7.0 (Insightful Corporation, Seattle, WA).
3. Results
A total of 107 subjects were screened for enrollment in
the denufosol versus placebo study, 90 (84%) were
randomized, with a final sample size of 89 in the intent-to-
treat (ITT) population. The reasons subjects failed screening
included: FEV1 % predicted b 75 (n=7), not clinically stable
(n=4), and unable or not willing to comply with protocol, be
present for required visits, or complete study procedureson
All groups combined (N=89)
40 mg (N=22) 60 mg (N=23)
18.0 (9.12) 16.2 (8.92) 16.1 (8.31)
11 (50) 8 (35) 50 (56)
22 (100) 22 (96) 88 (99)
10 (45) 7 (30) 39 (44)
9 (41) 11 (48) 35 (39)
3 (14) 5 (22) 15 (17)
157.82 (15.027) 152.48 (14.706) 153.55 (16.490)
53.76 (18.216) 49.46 (17.064) 49.59 (17.327)
2.623 (0.7775) 2.547 (0.8104) 2.559 (0.8198)
88.731 (8.9992) 96.353 (13.7590) 92.977 (11.0738)
66.498 (21.8684) 82.039 (24.0664) 78.155 (24.9051)
11 (50) 4 (17) 32 (36)
positive, or if the patient could not expectorate sputum and the patient had a
he past two years.
Fig. 2. Variability of spirometry as expressed by change in FEV1 (L) from
the screening visit to the baseline visit was reduced compared to historical
controls but not statistically significant. The difference between individual
subjects' FEV1 at screening and at visit 1 prior to dosing was calculated for
the denufosol Phase 2 study with and without central over-read, and these
differences are compared to differences seen in historical controls. Filled
circles represent the mean values and bars represent the 95% confidence
intervals.
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failing screening). A full description of the subjects involved
in this study is shown in Table 1. This population of subjects
has mild lung disease with an average FEV1 % predicted of
93% (SD=11). Thirty-nine (44%) were females, and the
mean age was 16.1 years (SD=8.3).
A total of 1418 spirometry values (709 FVC values and
709 FEV1 values) were obtained in the 89 subjects included
in the intent-to-treat population. Despite this very large
number of spirometry test sessions, the central over-reading
center needed to give feedback to specific sites regarding the
quality of the spirometry in only 5 instances. When specific
site data was compared to the final data picked by the central
over-reader, site data matched the central reading center's
data for all but 78 (5.5%) of the 1418 spirometry values (40
FEV1 and 38 FVC values differed). These differences
occurred when the over-reader did not agree with the site
with regards to the most appropriate spirometry data to
evaluate for the best FEV1 and FVC. The majority of these
differences were small. Only 35 (2.5%) values differed by
more than 50 mL for FEV1 and FVC combined. The mean
differences between the central over-read and site values for
FEV1 and FVC were 0.5 mL (SD=20 mL) and − 4.2 mL
(SD=55 mL) respectively. Given that almost 95% of the
differences were 0, it is not surprising that linear mixed-
effects models to account for repeated measures within
subject showed that within-subject variability for the
differences was much greater than between-subject variabil-
ity: 2 mL versus 19 mL for between- and within-subject SDs
of FEV1 differences, and 15 mL versus 54 mL for between-
and within-subject SDs for FVC differences. Not surpris-
ingly, there were a few “outliers”: the minimum and
maximum values of the differences were: −130 mL to
+ 350 mL for FEV1; and − 840 mL to + 320 mL for FVC.
Fig. 1 shows for each subject the mean of the absolute
values of the center minus site differences for FEV1 (mL),
plotted by site. There was no clear evidence that the
distribution of mean absolute differences differed by siteFig. 1. Mean absolute value of differences between the over-reading center
value and site value for FEV1 (mL) for each subject, plotted by site.(p=0.4 for FEV1, p=0.8 for FVC, Kruskal–Wallis test);
smaller sites appeared to do as well as larger sites with
relatively small differences between the over-read values and
site values.
3.1. Comparison with historical controls
One of the important questions that we posed was
whether the use of centralized spirometry with central over-
read resulted in a reduction of the variability of spirometry
used in CF clinical trials. The only definitive way to answer
this question would be to randomize subjects to having
centralized spirometry versus no centralized spirometry and
assess the impact of the two programs, but this study design
would be extremely challenging to fund. Comparing pre-
dose data with pre-dose data from historical controls from
CF clinical trials with similar inclusion criteria and lung
function may represent the best alternative.
Pre-dose data at two separate visits from the denufosol
study was available for 92 subjects: the 89 subjects in the
ITT population, as well as two subjects who were dropped
from the study because they did not meet the “FEV1 (L)
within 12% on two separate occasions” inclusion criterion,
and one subject who was dropped from the study after Visit 2
due to increased cough. Pre-dose data at two separate visits
from two previous studies conducted with the CF TDN was
available for 52 subjects. When compared with historical
controls with similar lung function, the absolute difference in
lung function (FEV1) from screening to baseline was lower
in the denufosol study (Fig. 2), but not statistically
significant (p=0.2 for denufosol with over-read versus
historical control; p=0.2 for denufosol without over-read
versus historical control; two-sample t-test). The mean
Fig. 3. Differences in variability between the denufosol study and historical
studies can possibly be attributed to differences in the duration in days
between screening and visit 1 spirometry. The difference between individual
subjects' FEV1 at screening and at visit 1 prior to dosing are plotted against
the days between screening and visit 1 (○ represents the denufosol study
with over-read; ▴ represents historical controls). Slope for denufosol=
− 0.008, slope for historical controls=0.006, p=0.03).
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(124 mL versus 102 mL) with a larger standard deviation of
the difference (130 mL versus 77 mL). We also looked at the
difference between screening and baseline lung function
(FEV1) with and without the central over-read. There was no
evidence that the central over-read in and of itself reduced
variability compared merely to centralized spirometry with
uniform spirometers at each site (p=0.5, paired t-test). Mean
absolute difference in FEV1 between screening and baseline
was 103 mL without over-read versus 102 mL with over-
read, and the standard deviation of the absolute difference
was 79 mL without over-read versus 77 mL with over-read.
Similar results were obtained for FVC.
Table 2 shows variance components estimates for raw
FEV1 (L) values using just the screening and baseline pre-
dose data based on linear mixed-effects models. Although
the within-subject variability as a percentage of total
variability is slightly greater for the historical controls
(1.8% versus 1.2%), the confidence intervals for these
variance components makes it clear that there is no firm
evidence that within-subject variability has been reduced in
the denufosol study compared to the historical controls, with
or without over-reading. The fact that within-subject
variability as a percentage of total variability is less than
2% for the historical controls is a testament to the high-level
of quality control in these historical studies.
One concern with this historical comparison is that the
duration of time in days from the screening visit to the
baseline visit would be related either linearly or non-linearly
to the variation in lung function. Thus, if the historical control
group had a much greater period of time pass between
screening and baseline, this alone could explain the reduction
in variation observed in our study. When we examined the
relationship between the number of days between screening
and baseline spirometry values, we found that in fact a much
higher proportion of visits for the historical controls were two
weeks apart compared to the denufosol study, for which most
visits were at most one week apart (Fig. 3). Variability for the
historical controls increased with days between visits
(slope=0.006, 95% CI=[− 0.001, 0.012]), while variability
for the denufosol study decreased with days between visits
(slope=− 0.008, 95% CI= [− 0.016, 0.001]), but neitherTable 2
Variance components estimates for raw FEV1 (L) values using just screening
















0.82 [0.71, 0.95] 0.09 [0.08, 0.10] 1.2%
Denufosol without
Over-read
0.82 [0.71, 0.95] 0.09 [0.08, 0.11] 1.2%
Historical 0.93 [0.76, 1.13] 0.13 [0.10, 0.15] 1.8%slope was significantly different from 0. Thus, we found no
clear effect of days between visits and variability.
4. Discussion
Site spirometry in the denufosol versus placebo CF
clinical trial was of high quality with low rate of over-read
from the central reading center. In comparison to other CF
clinical trials conducted within the CF TDN, a program of
centralized reading reduced within-subject variability that
did not reach statistical significance. The central over-read
appeared to play a minimal role in reducing variability. In the
current study, high quality of spirometry diminished the role
of centralized spirometry. Overall, decreasing variability in
lung function measurements will be necessary if we are to be
able to move forward with more therapies in rare lung
diseases like cystic fibrosis. As clinical research in CF
expands to less experienced research sites, the quality and
variability of spirometry may worsen.
Most of the evidence regarding the variability of spirometry
and the effect of quality assurance programs (like centralized
spirometry) come from large epidemiologic and randomized
clinical trials [8,9,11,12]. The effect of these programs has
been assessed primarily using before/after designs and by
comparing their results to those of other large cohorts, much
like our design. The primary evidence to support the use of
quality assurance programs has come form the Multiple Risk
Factor Intervention Trial (MRFIT) [7], Lung Health Study
(LHS) [8–10], the National Health and Nutrition Examination
Survey (NHANES) III study [20,21], the Children's Health
Study [11], and most recently asthma clinical trials [12].
The earliest report of quality oversight of spirometry
using a 10-liter Stead–Wells water-filled spirometer in a
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conclusion from this study was that centralized training on
testing techniques and spirometer maintenance along with
periodic retraining during long trials is strongly recom-
mended. In the LHS, 73,000 current cigarette smokers ages
45 to 60 were screened at 10 sites on three occasions prior to
enrollment in a prospective randomized clinical trial to
assess the effect of smoking cessation and an inhaled
bronchodilator on annual lung function decline over 5 years
[8]. Specialized software with real-time displays helped
coach both the subject and the technician if tests were
inadequate, giving precise instructions to perform an
adequate test. Eighteen months after study initiation, central
reading was started because of excessive variability noted
early in the study. The coefficient of variation found in this
study was 5.8% after repeating the spirometry at two time
points separated by 30–90 days. This was much less than
that noted in earlier cohort studies from a single time point
(range 9.9% to 20.2% in smokers) [22–24]. Sustained
improved quality scores of spirometry occurred only after
central reading/feedback and scoring was initiated. Three
other studies have reported results and experience with
centralized spirometry [11,12,20,21]. These studies noted
that centralized spirometry was associated with minimal
rates of unacceptable spirometry loops [20,21], low rates
spirometry loops that failed to meet ATS standards [11], and
low rates of failing spirometry using a spirometry grading
system (A to F with the best studies achieving a grade of A)
[12]. Of all of these reported studies, only the LHS
convincingly showed the impact on centralized spirometry.
Experience from the LHS, NHANES, the Child's Health
Study, and asthma clinical trials does not necessarily apply to
the CF clinical research setting. The study sites in these
examples used both community-based and academic sites
that may or may not have had prior experience conducting
clinical research in lung disease. In comparison, the majority
of CF care is delivered at specialized centers with a multi-
disciplinary approach, with a significant percentage of the
centers located at academic medical centers. The centers in
our study were all tertiary referral CF centers with experience
doing clinical research in CF with established standard
operating procedures for the conduct of spirometry. Thus, it
was unclear whether we could show any benefit of
centralized spirometry in this specialized setting.
The reason for the reduced variability in CF clinical trials
is likely multi-factorial. Certainly, intrinsic subject charac-
teristics may be important in explaining variability in
spirometry, but these factors cannot be routinely controlled
for in a clinical trial other than excluding specific subject
populations. Reasons that our sample showed reduced
though not statistically significant variability compared to
historic controls include: different subject populations,
protocol exclusions, site personnel who are very familiar
with the spirometry procedure, site training, the use of
uniform spirometer, and experience with spirometry in
clinical trial. Additional information from the literature hasnoted that subject experience with spirometry in and of itself
is an important predictor of non-intrinsic variability in
spirometry [12,25–28]. Given that the historical data came
from these same sites within the prior 3 years and included
similar subject populations based on FEV1, we believe most
of the reduction in variability we noted was due to the use of
uniform spirometers and detailed site training at the start of
the study. Our study was also of short duration in comparison
to some of those mentioned above. Our sites had also already
gone through two internal reviews of spirometry (169 and
160 spirograms respectively) conducted by Dr. Paul Enright.
In the first review, only 1.2% of 169 spirometry studies did
not fulfill ATS standards — this all prior to the introduction
of centralized spirometry. In our current study, we found no
clear evidence that the act of central reading had much
impact on the variability of spirometry conducted in this
study. Clearly, quality assurance programs in spirometry
utilized in clinical trials are important. It remains to be
proven which component of a program that includes
centralized spirometry is critical to reducing variability in
spirometry values. Our data may not apply to CF subjects
with FEV1 below 75% of predicted; further assessment of
centralized spirometry is needed in this population of CF
patients.
A component of test assessment not formally addressed in
this analysis is accuracy; an ideal test has both high precision
(low variability) and high accuracy (low bias). We focused
on variability because accuracy cannot be formally assessed
in spirometry without the availability of a gold standard. We
did not have data regarding the actual experience of the
technicians performing the spirometry nor the volume at
each given site. Thus, issues related to the size of a site are
much more complex and relate to training and experience.
In conclusion, we believe that centralized spirometry
(instrument standardization; site/technician training, central-
ized review of data by an expert over-reader, and immediate
feedback to sites on poor quality sessions) has the potential to
decrease test variability. However, we found that for CF
clinical trials within the established CF TDN, having central
over-read did not significantly enhance spirometry quality. We
did see a non-statistically significant reduction in variability
with centralized spirometry which may justify it use in further
clinical trials. Careful training of the sites, uniform spirom-
eters, centralized transfer of data may reduce variability and
improve our capacity to assess change due to treatments
particularly as less experienced research sites are used in the
setting of larger and more numerous CF clinical trials.
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